MiR-22-3p suppresses NSCLC cell migration and EMT via targeting RAC1 expression

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• microRNA-22-3p (miR-22-3p) exhibits tumor-suppressive roles in various cancers.
• The specific function and mechanism of miR-22-3p in non-small cell lung cancer (NSCLC) are not well-established.

Purpose of the Study:

• To investigate the biological function and molecular mechanism of miR-22-3p in NSCLC.
• To explore the potential of the miR-22-3p/RAC1 axis as a therapeutic target for NSCLC.

Main Methods:

• Quantitative real-time PCR (RT-qPCR) and TCGA database analysis to assess miR-22-3p expression.
• In vitro assays to evaluate the effects of miR-22-3p on NSCLC cell migration and epithelial-mesenchymal transition (EMT).
• Luciferase reporter assays to identify miR-22-3p target genes, specifically investigating RAC1.

Main Results:

• miR-22-3p expression was significantly decreased in NSCLC tissues and cells compared to normal controls.
• Lower miR-22-3p levels correlated with lymph node metastasis and larger tumor size.
• Overexpression of miR-22-3p inhibited NSCLC cell migration and EMT, while its silencing promoted these processes.
• RAS-related C3 botulinum toxin substrate 1 (RAC1) was identified as a direct target of miR-22-3p.
• miR-22-3p suppressed cell migration and EMT by downregulating RAC1, an effect reversible by RAC1 overexpression.

Conclusions:

• miR-22-3p functions as a tumor suppressor in NSCLC.
• The miR-22-3p/RAC1 signaling pathway plays a crucial role in regulating NSCLC cell migration and EMT.
• Targeting the miR-22-3p/RAC1 axis offers a promising therapeutic strategy for NSCLC intervention.